Cargando…
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
Middle East respiratory syndrome coronavirus (MERS-CoV), a highly pathogenic coronavirus in the same Betacoronavirus genus and Coronaviridae family as SARS-CoV-2, continues to post a threat to human health. Mortality remains high; therefore, there is a need to develop effective vaccines to prevent M...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278997/ https://www.ncbi.nlm.nih.gov/pubmed/37336390 http://dx.doi.org/10.1016/j.virusres.2023.199156 |
_version_ | 1785060585614868480 |
---|---|
author | Tai, Wanbo Zheng, Jian Zhang, Xiujuan Shi, Juan Wang, Gang Guan, Xiaoqing Zhu, Jiang Perlman, Stanley Du, Lanying |
author_facet | Tai, Wanbo Zheng, Jian Zhang, Xiujuan Shi, Juan Wang, Gang Guan, Xiaoqing Zhu, Jiang Perlman, Stanley Du, Lanying |
author_sort | Tai, Wanbo |
collection | PubMed |
description | Middle East respiratory syndrome coronavirus (MERS-CoV), a highly pathogenic coronavirus in the same Betacoronavirus genus and Coronaviridae family as SARS-CoV-2, continues to post a threat to human health. Mortality remains high; therefore, there is a need to develop effective vaccines to prevent MERS-CoV infection. The receptor-binding domain (RBD) within the MERS-CoV spike (S) protein is a critical vaccine target. The latest mRNA technology has enabled rapid development of much-needed vaccines with high efficiency and scalable manufacturing capacity. Here, we designed a mRNA vaccine encoding the RBD of MERS-CoV S protein (RBD-mRNA) and evaluated its immunogenicity and protective efficacy in a mouse model. The data showed that nucleoside-modified RBD-mRNA, but not RBD-mRNA lacking the nucleoside modification, was stable and elicited broadly and durable neutralizing antibody and cellular immune responses, which neutralized the original strain and multiple MERS-CoV variants. Among all immunization routes tested, the intradermal route was appropriate for this RBD-mRNA to induce strong B-cell responses and the highest neutralizing antibody titers. Importantly, injection of nucleoside-modified RBD-mRNA through the intradermal route protected immunized mice against challenge with MERS-CoV. This protection correlated with serum neutralizing antibody titers. Overall, we have developed an effective MERS-CoV RBD-based mRNA vaccine (with potential for further development) that prevents infection by divergent strains of MERS-CoV. |
format | Online Article Text |
id | pubmed-10278997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-102789972023-06-21 MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection Tai, Wanbo Zheng, Jian Zhang, Xiujuan Shi, Juan Wang, Gang Guan, Xiaoqing Zhu, Jiang Perlman, Stanley Du, Lanying Virus Res Article Middle East respiratory syndrome coronavirus (MERS-CoV), a highly pathogenic coronavirus in the same Betacoronavirus genus and Coronaviridae family as SARS-CoV-2, continues to post a threat to human health. Mortality remains high; therefore, there is a need to develop effective vaccines to prevent MERS-CoV infection. The receptor-binding domain (RBD) within the MERS-CoV spike (S) protein is a critical vaccine target. The latest mRNA technology has enabled rapid development of much-needed vaccines with high efficiency and scalable manufacturing capacity. Here, we designed a mRNA vaccine encoding the RBD of MERS-CoV S protein (RBD-mRNA) and evaluated its immunogenicity and protective efficacy in a mouse model. The data showed that nucleoside-modified RBD-mRNA, but not RBD-mRNA lacking the nucleoside modification, was stable and elicited broadly and durable neutralizing antibody and cellular immune responses, which neutralized the original strain and multiple MERS-CoV variants. Among all immunization routes tested, the intradermal route was appropriate for this RBD-mRNA to induce strong B-cell responses and the highest neutralizing antibody titers. Importantly, injection of nucleoside-modified RBD-mRNA through the intradermal route protected immunized mice against challenge with MERS-CoV. This protection correlated with serum neutralizing antibody titers. Overall, we have developed an effective MERS-CoV RBD-based mRNA vaccine (with potential for further development) that prevents infection by divergent strains of MERS-CoV. Elsevier 2023-06-19 /pmc/articles/PMC10278997/ /pubmed/37336390 http://dx.doi.org/10.1016/j.virusres.2023.199156 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Tai, Wanbo Zheng, Jian Zhang, Xiujuan Shi, Juan Wang, Gang Guan, Xiaoqing Zhu, Jiang Perlman, Stanley Du, Lanying MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title | MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title_full | MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title_fullStr | MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title_full_unstemmed | MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title_short | MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection |
title_sort | mers-cov rbd-mrna vaccine induces potent and broadly neutralizing antibodies with protection against mers-cov infection |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278997/ https://www.ncbi.nlm.nih.gov/pubmed/37336390 http://dx.doi.org/10.1016/j.virusres.2023.199156 |
work_keys_str_mv | AT taiwanbo merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT zhengjian merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT zhangxiujuan merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT shijuan merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT wanggang merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT guanxiaoqing merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT zhujiang merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT perlmanstanley merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection AT dulanying merscovrbdmrnavaccineinducespotentandbroadlyneutralizingantibodieswithprotectionagainstmerscovinfection |